Jason E Farrar, MD

Research Program: Cancer Biology Faculty Rank: Professor Campus: Arkansas Children's Hospital College: College of Medicine Department: Peds Hematology

Cancer Research Interest

• Disease Site Focus: Pediatric Oncology, Hematologic Malignancies
• Research Focus Area: Treatment, Informatics, Detection, Diagnosis/ Prognosis
• Type of Research: Clinical, Translational
• Research Interest Statement: I am a pediatric hematologist/oncologist with clinical interests in childhood leukemia, lymphomas and cancer-prone disorders such as inherited bone marrow failure and myelodysplastic syndromes. Our research program focuses on understanding the genetic basis of abnormal bone marrow function that underlies these diseases in children in order to identify new therapeutic options and improve treatment outcomes.

Contact Information

• Email Address: JEFARRAR@UAMS.EDU
• Profiles Research Networking Software: View Profile

Recent Publications

• Choudhury SR, Kaushal A, Biswas P, [et al., including Farrar JE]. Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2-driven pediatric acute megakaryoblastic leukemia. Genes & diseases. 2026 13(1):101843. PMID: 41141393.
• Shimamura A, Maschan A, Bennett C, [et al., including Farrar JE]. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood advances. 2025 9(15):3728-3738. PMID: 40315366.
• Reed HD, Do H, Weller EA, [et al., including Farrar JE]. Lymphoid malignancies in patients with Shwachman-Diamond syndrome. Blood. 2025 145(21):2528-2532. PMID: 40090004. PMCID: PMC12163733.
• Liu Z, Tsai T, Zuo B, [et al., including Farrar JE]. The sow vaginal and gut microbiota associated with longevity and reproductive performance. Journal of animal science and biotechnology. 2025 16(1):6. PMID: 39762999. PMCID: PMC11705881.
• Doan DT, Strebeck PV, Tran AD, [et al., including Farrar JE]. Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency. The journal of allergy and clinical immunology. Global. 2024 3(4):100313. PMID: 39221430. PMCID: PMC11364118.
• Wlodarski MW, Vlachos A, Farrar JE, [et al.]. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology. 2024 11(5):e368-e382. PMID: 38697731.
• Abla O, Ries RE, Triche TJ Jr, [et al., including Farrar JE]. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood advances. 2024 8(8):2005-2017. PMID: 38306602. PMCID: PMC11024924.
• Appell LE, Mack JM, Farrar JE, [et al.]. Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease. Pediatrics. 2024 153(4). PMID: 38511235.
• Frett B, Stephens KE, Koss B, [et al., including Farrar J]. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. Cancer science. 2024 115(3):963-973. PMID: 38226414. PMCID: PMC10920984.
• Farrar JE, Othus M, Wang YC, [et al.]. Reply to Z.R. McCaw et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 41(27):4447. PMID: 37390387. PMCID: PMC10522099.
• Bertrums EJM, Smith JL, Harmon L, [et al., including Farrar JE]. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023 108(8):2044-2058. PMID: 36815378. PMCID: PMC10388277.
• Sun JM, Chow WY, Xu G, [et al., including Farrar JE]. The Role of FAS Receptor Methylation in Osteosarcoma Metastasis. International journal of molecular sciences. 2023 24(15). PMID: 37569529. PMCID: PMC10418590.
• Farrar JE, Smith JL, Othus M, [et al.]. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 41(16):2949-2962. PMID: 36795987. PMCID: PMC10414715.
• Huang BJ, Smith JL, Farrar JE, [et al.]. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nature communications. 2022 13(1):5487. PMID: 36123353. PMCID: PMC9485122.
• Hu Y, Caldwell KJ, Onciu M, [et al., including Farrar JE]. CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood advances. 2022 6(2):521-527. PMID: 34710216. PMCID: PMC8791570.
• Huang BJ, Smith J, Wang J, [et al., including Farrar JE]. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood advances. 2021 5(23):4963-4968. PMID: 34547772. PMCID: PMC9153007.
• Douglass DP, Stine KC, Farrar JE. A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance. Journal of pediatric hematology/oncology. 2021 43(8):e1220-e1222. PMID: 33633026.
• Gill PS, Yu FB, Porter-Gill PA, [et al., including Farrar JE]. Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. Journal of personalized medicine. 2021 11(5). PMID: 34064668. PMCID: PMC8150685.